Document:

EX-10.1

 Exhibit 10.1 

EXECUTION VERSION 

STOCK PURCHASE AGREEMENT 

By and Between 
 INCYTE
CORPORATION 
 and 

CALITHERA BIOSCIENCES, INC. 

Dated as of January 27, 2017 

 CALITHERA BIOSCIENCES, INC. 

STOCK PURCHASE AGREEMENT 

THIS STOCK PURCHASE AGREEMENT (the “Agreement”) is made and entered into as of January 27, 2017 (the “Signing
Date”), by and between Calithera Biosciences, Inc., a Delaware corporation (the “Company”), and Incyte Corporation, a Delaware corporation (the “Purchaser”). 

WHEREAS, the Company and the Purchaser are entering into that certain Collaboration and License Agreement of even date herewith (the
“Collaboration Agreement”); 
 WHEREAS, the obligations in the Collaboration Agreement are conditioned upon the execution
and delivery of this Agreement, pursuant to which the Company will issue and sell to the Purchaser a number of shares of its common stock, par value $0.0001 per share (the “Common Stock”) as provided for herein; and 

WHEREAS, the Purchaser desires to purchase, and the Company desires to sell, the shares of Common Stock on the terms and conditions set forth
herein; 
 NOW, THEREFORE, in consideration of the foregoing recitals and the mutual promises, representations, warranties, and covenants
hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 

1.    Definitions. When used in this Agreement, the following terms shall have the
respective meanings specified below: 
 “Action” shall mean any action, cause or action, suit, prosecution, investigation,
litigation, arbitration, hearing, order, claim, complaint or other proceeding (whether civil, criminal, administrative, investigative or informal) by or before any Governmental Authority or arbitrator. 

“Affiliate” shall mean, with respect to any Person, another Person which controls, is controlled by or is under common
control with such Person. A Person shall be deemed to control another Person if such Person possesses, directly or indirectly, the power to direct or cause the direction of the management and policies of such Person, whether through the ownership of
voting securities, by contract or otherwise. Without limiting the generality of the foregoing, a Person shall be deemed to control another Person if any of the following conditions is met: (i) in the case of corporate entities, direct or indirect
ownership of more than fifty percent (50%) of the stock or shares having the right to vote for the election of directors, and (ii) in the case of non-corporate entities, direct or indirect ownership of more than fifty percent (50%) of the equity
interest with the power to direct the management and policies of such non-corporate entities. For the purposes of this Agreement, in no event shall the Purchaser or any of its Affiliates be deemed Affiliates of the Company or any of its Affiliates,
nor shall the Company or any of its Affiliates be deemed Affiliates of the Purchaser or any of its Affiliates. 

  
 1 

 “Base Prospectus” means the base prospectus forming part of that certain
registration statement on Form S-3 (File No. 333-207905) as declared effective by the SEC on November 24, 2015. 
 “Board of
Directors” means the board of directors of the Company. 
 “Business Day” shall mean any day except Saturday,
Sunday and any day on which banking institutions in New York, New York, generally are closed as a result of federal, state or local holiday. 

“Change of Control” shall mean, with respect to a Person, any of the following events: (i) any Person is or becomes the
beneficial owner (as such term is defined in Rule 13d-3 under the Exchange Act, except that a Person shall be deemed to have beneficial ownership of all shares that any such Person has the right to acquire, whether such right which may be exercised
immediately or only after the passage of time), directly or indirectly, of a majority of the total voting power represented by all shares of such Person’s outstanding capital stock; (ii) such Person consolidates with or merges into another
corporation or entity, or any corporation or entity consolidates with or merges into such Person, other than (A) a merger or consolidation which would result in the voting securities of such Person outstanding immediately prior to such merger or
consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or any parent thereof) a majority of the combined voting power of the voting securities of such Person or
such surviving entity or any parent thereof outstanding immediately after such merger or consolidation, or (B) a merger or consolidation effected to implement a recapitalization of such Person (or similar transaction) in which no Person becomes the
beneficial owner, directly or indirectly, of a majority of the total voting power of all shares of capital stock of such Person, or (iii) such Person conveys, transfers or leases all or substantially all of its assets, to any Person other than a
wholly owned Affiliate of such Person. 
 “Code” shall mean the United States Internal Revenue Code of 1986, as amended.

 “Common Stock Equivalents” means any securities of the Company which would entitle the holder thereof to acquire at any
time shares of Common Stock, including, without limitation, any debt, preferred shares, rights, options, warrants or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof
to receive, shares of Common Stock. 
 “Consent” shall mean any approval, authorization, consent, license, franchise,
Order, registration, notification, permit, certification, clearance, waiver or other confirmation of or by a Governmental Authority or other Person. 

“Contract” shall mean, with respect to any Person, any written or oral agreement, contract, commitment, indenture, note,
bond, loan, license, sublicense, lease, sublease, undertaking, statement of work or other arrangement to which such Person is a party or by which any of its properties or assets are subject. 

“Employee Benefit Plan” shall mean any “employee benefit plan” (as such term is defined in Section 3(3) of ERISA,
whether or not subject to ERISA), any severance, 

  
 2 

 
employment, incentive or bonus, retention, change in control, deferred compensation, termination pay, profit sharing, retirement, welfare, post-employment welfare, fringe benefit, vacation or
paid time off, equity or equity-based or any other plan, policy, program, agreement, contract or arrangement (i) that is sponsored, maintained, contributed to, or required to be contributed to by the Company or under or with respect to which the
Company has any current or contingent liability or obligation, or (ii) that provides benefits or compensation to any employee, director, or officer of the Company or any other person performing services for the Company (including any leased employee
or individual co-employed by a “professional employer organization”). 
 “Environmental Law” shall mean all
national, supra-national, federal, state, local and foreign Laws concerning public health and safety, worker health and safety, pollution or protection of the environment; including without limitation all those relating to the generation, handling,
transportation, treatment, storage, disposal, release, exposure to or cleanup of hazardous materials, substances or wastes, including petroleum, asbestos, polychlorinated biphenyls, asbestos, noise or radiation. 

“ERISA” shall mean the United States Employee Retirement Income Security Act of 1974, as amended, and the rulings and
regulations thereunder. 
 “Exchange Act” shall mean the U.S. Securities Exchange Act of 1934, as amended, and the rules
and regulations promulgated thereunder. 
 “Exempt Issuance” means the issuance of (a) shares of Common Stock or options to
employees, consultants, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose and in existence on the date of this Agreement as such plan is constituted on the date of this Agreement, by a majority
of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose, unless otherwise agreed to by the non-employee members of the Board of Directors, (b)
securities upon the exercise or exchange of or conversion of any Common Stock Equivalents issued and outstanding on the date of this Agreement, provided that such securities have not been amended on or after the date of this Agreement to increase
the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities, (c) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of
the Company, provided that any such issuance shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities, and (d) an
“at-the-market” offering of common stock. 
 “Governmental Authority” shall mean any court, agency, authority,
department, regulatory body or other instrumentality of any government or country or of any national, federal, state, provincial, regional, county, city or other political subdivision of any such government or country or any supranational
organization of which any such country is a member. 
 “Health Care Laws” means all applicable Laws relating to pricing,
marketing, promotion, sale, distribution, coverage, or reimbursement of a drug, biological or medical device. 

  
 3 

 “Indebtedness” shall mean, with respect to any Person at any applicable time of
determination, without duplication, (a) all liabilities and obligations for borrowed money, (b) all liabilities and obligations evidenced by bonds, debentures, notes or other similar instruments or debt securities, (c) all liabilities and
obligations under or in respect of swaps, hedges or similar instruments, (d) all liabilities and obligations in respect of letters of credit and similar instruments, (e) all liabilities and obligations (contingent or otherwise) arising from or in
respect of (i) deferred compensation arrangements, (ii) pension plans, or (iii) amounts payable as a result of the consummation of the transactions contemplated hereby (regardless of whether any additional event, in addition to the consummation of
the transactions contemplated hereby, is required to give rise to such liabilities and obligations), (f) all guaranties in connection with any of the foregoing, and (g) all accrued interest, prepayment premiums, fees, penalties, expenses or other
amounts payable in respect of any of the foregoing. 
 “Intellectual Property” shall mean all intellectual property and
other similar proprietary rights in any jurisdiction, including such rights in and to: (a) any patent (including all reissues, divisions, continuations, continuations-in-part and extensions thereof), patent application, patent disclosure or other
patent right, (b) any trademark, service mark, trade name, business name, brand name, slogan, logo, trade dress and all other indicia of origin together with all goodwill associated therewith, and all registrations, applications for registration,
and renewals for any of the foregoing, (c) any copyright, work of authorship (whether or not copyrightable), design, design registration, database rights, and all registrations, applications for registration, and renewals for any of the foregoing
(and including in all website content and software), (d) any Internet domain names, and (e) any trade secret, confidential information, know-how and inventions, including processes and formulations. 

“Knowledge” shall mean knowledge after reasonable investigation of the officers of the Company, as such term is defined in
Exchange Act Rule 16a-1(f). 
 “Law” or “Laws” shall mean all laws, statutes, rules, regulations, orders,
judgments, injunctions and ordinances of any Governmental Authority. 
 “Leased Real Property” shall mean all leasehold or
subleasehold estates and all other rights to use or occupy any land, buildings, structures, improvements, fixtures or other interest in real property held by the Company pursuant to any Lease. 

“Leases” shall mean all leases, subleases, licenses, concessions and other Contracts pursuant to which the Company holds any
Leased Real Property as tenant, sublease, licensee or concessionaire (including the rights to all security deposits and other amounts and instruments deposited by or on behalf of the Company thereunder) and all material amendments, extensions,
renewals, guaranties and other agreements with respect thereto. 
 “Liens” shall mean a lien, charge, security interest,
encumbrance, right of first refusal, preemptive right or other restriction. 
 “Material Adverse Effect” shall mean any
change, event or occurrence (each, an “Effect”) that, individually or when taken together with all other Effects, has had or is reasonably likely to have (a) a material adverse effect on the business, condition (financial or

  
 4 

 
other), assets, liabilities or results of operations of the Company, taken as a whole, or (b) a material adverse effect on the Company’s ability to timely perform its obligations under, or
timely consummate any of the transactions contemplated by, the Transaction Agreements, (including the sale of the Shares, in accordance with the terms of this Agreement), to the extent that any such Effect results from or arises out of: (i)
changes occurring after the date hereof in conditions in the United States of America or global economy or capital or financial markets generally, including changes in interest or exchange rates, (ii) changes occurring after the date hereof in
general legal, regulatory, political, economic or business conditions or changes to U.S. GAAP or interpretations thereof occurring after the date hereof that, in each case, generally affect the biotechnology or biopharmaceutical industries, (iii)
acts of war, sabotage or terrorism occurring after the date hereof, or any escalation or worsening of any such acts of war, sabotage or terrorism, or (iv) earthquakes, hurricanes, floods or other natural disasters occurring after the date hereof,
provided, however, that any Effect referred to in clauses (i)-(iv) above shall be taken into account in determining whether a Material Adverse Effect has occurred or would be reasonably likely to occur only if such Effect has had or would be
reasonably likely to have a disproportionate effect on the Company compared to other participants in the biotechnology or biopharmaceutical industries. 

“Material Contract” shall mean any Contract entered into by the Company that is required to be disclosed as an exhibit to any
filing made by the Company pursuant to the Exchange Act. 
 “NASDAQ” shall mean the NASDAQ Stock Market LLC. 

“Order” shall mean any assessment, award, decision, injunction, judgment, order, ruling, verdict or writ entered, issued,
made, or rendered by any court, administrative agency, or other Governmental Authority or by any arbitrator. 
 “Permitted
Liens” shall mean (a) mechanics’, materialman’s, workmens’, repairmens’, warehousemen’s, supplier’s, vendor’s, carrier’s and other similar Liens arising or incurred in the ordinary course of business
by operation of Law securing amounts that are not yet due and payable, (b) Liens for Taxes, assessments and other charges of Governmental Authorities not yet due and payable, (c) Liens arising under original purchase price conditional sales
Contracts and equipment leases with third parties, (d) pledges or deposits to secure obligations under workers or unemployment compensation Laws or to secure other statutory obligations, (e) easements, covenants, conditions and restrictions of
record affecting title to the Leased Real Property which do not or would not materially impair the use or occupancy of any Leased Real Property in the operation of the business conducted thereon as of the date of this Agreement, and (f) any zoning,
or other governmentally established restrictions of encumbrances. 
 “Person” shall mean any individual, partnership,
limited liability company, firm, corporation, trust, unincorporated organization, government or any department or agency thereof or other entity, as well as any syndicate or group that would be deemed to be a Person under Section 13(d)(3) of the
Exchange Act. 
 “Prospectus” means the Base Prospectus and Prospectus Supplement to the Registration Statement. 

  
 5 

 “Prospectus Supplement” means the supplement to the Base Prospectus complying
with Rule 424(b) of the Securities Act as filed with the SEC relating to the issuance of the Shares to the Purchaser. 

“Registration Statement” means that certain registration statement on Form S-3 (File No. 333-207905) as declared effective by
the SEC on November 24, 2015. 
 “SEC” shall mean the U.S. Securities and Exchange Commission. 

“Securities Act” shall mean the U.S. Securities Act of 1933, as amended, and the rules and regulations promulgated
thereunder. 
 “Tax” or “Taxes” shall mean (a) any federal, state, local, or non-U.S. income, gross
receipts, license, payroll, employment, excise, severance, stamp, occupation, premium, windfall profits, environmental (including taxes under Section 59A of the Code), customs duties, capital stock, franchise, profits, withholding, social security
(or similar), unemployment, disability, real property, personal property, sales, use, transfer, unclaimed property or escheat (or similar), registration, value added, alternative or add-on minimum, estimated, or other tax of any kind whatsoever,
including any interest, penalty, or addition thereto, whether disputed or not, (b) any liability for or in respect of the payment of any amount of a type described in clause (a) of this definition as a result of being a member of an affiliated,
combined, consolidated, unitary or other group for Tax purposes, or (c) any liability for or in respect of the payment of any amount described in clauses (a) or (b) of this definition as a transferee or successor, by Contract or otherwise. 

“Tax Return” shall mean any return, declaration, report, claim for refund, or information return or statement relating to
Taxes, including any schedule or attachment thereto, and including any amendment thereof. 
 “Third Party” shall mean any
Person (other than a Governmental Authority) other than the Purchaser, the Company or any Affiliate of the Purchaser or the Company. 

“Trading Day” shall mean a day on which the Trading Market is open for trading. 

“Trading Market” shall mean the NASDAQ Global Select Market to the extent that the Common Stock is then listed on such
exchange. 
 “Transaction Agreements” shall mean this Agreement and the Collaboration Agreement. 

“Transfer Agent” shall mean American Stock Transfer & Trust Company, LLC, or any successor transfer agent of the Company.

 “WARN Act” shall mean the Worker Adjustment and Retraining Notification Act of 1988, as amended and any similar or
related Law. 

  
 6 

 2.    Closing, Delivery and Payment. 

2.1    Closing. Subject to the terms and conditions hereof, and in reliance on the representations,
warranties, covenants and other agreements hereinafter set forth, at the Closing (as hereinafter defined), the Company hereby agrees to sell to the Purchaser, and the Purchaser agrees to purchase, 1,720,430 shares of Common Stock (the
“Shares”), at a purchase price of $4.65 per share of Common Stock (the “Closing”), free and clean of all Liens, for an aggregate purchase price of Eight Million Dollars ($8,000,000) (the “Purchase
Price”). The issuance and sale of the Shares will be effected pursuant to the Registration Statement. The Closing shall take place remotely via the exchange of documents and signatures at 10:00 a.m. on the third (3rd) Business Day immediately following the date on which the last of the conditions set forth in Article 6 has been satisfied or waived (other than those conditions that by their nature can only be
satisfied at the Closing), or at such other time as the Company and Purchaser shall mutually agree (which time and place are designated as the “Closing Date”). 

2.2    Delivery and Payment. At the Closing, subject to the terms and conditions hereof, the Company
will instruct the Transfer Agent to deliver to the Purchaser, via book entry to the applicable balance account registered in the name of the Purchaser, the Shares, against payment of the Purchase Price in U.S. dollars by wire transfer made payable
to the order of the Company. 
 2.3    Deliveries at Closing. 

(a)    Deliveries by the Company. At the Closing, the Company shall deliver or cause to be delivered to the
Purchaser the following items: 
 (i)    A copy of Prospectus as filed with the SEC with respect to the Shares;

 (ii)    evidence of the filing of the Listing of Additional Shares notification to NASDAQ as it relates to
the Shares; 
 (iii)    legal opinion of Cooley LLP, the Company’s counsel, dated as of the Closing Date in
the form reasonably acceptable to the Purchaser; 
 (iv)    a copy of the irrevocable instructions to the
Transfer Agent instructing the Transfer Agent to deliver, on an expedited basis, the Shares to the Purchaser, via a book entry position in an account registered in the name of the Purchaser at the Transfer Agent; 

(v)    a compliance certificate, executed by the Chief Executive Officer of the Company, dated as of the Closing
Date, to the effect that the conditions specified in Section 6.1 have been satisfied; 
 (vi)    a certificate
of the Company’s Secretary certifying as to (A) the Company’s certificate of incorporation and bylaws, (B) the resolutions of the Board of Directors approving this Agreement and the transactions contemplated hereby, and (C) good standing
certificates with respect to the Company from the applicable authority(ies) in Delaware and California, dated a recent date before the Closing; and 

  
 7 

 (vii)    all such other documents, certificates and instruments as
the Purchaser may reasonably request in order to give effect to the transactions contemplated hereby and by the other Transaction Agreements. 

(b)    Deliveries by the Purchaser. At the Closing, the Purchaser shall deliver or cause to be
delivered to the Company the Purchase Price, by wire transfer of immediately available funds to one or more accounts designated by the Company, such designation to be made no later than two (2) Business Days prior to the Closing Date. 

2.4    Withholding. The Purchaser and its agents shall be entitled to deduct and withhold from any
consideration payable hereunder any amounts it may be required to deduct and withhold under any applicable Tax Law. Amounts withheld under this Section 2.4 and paid over to the appropriate Governmental Authority shall be treated for all purposes of
this Agreement as having been paid to the Person in respect of which such deduction and withholding was made. The Purchaser shall provide written notice to the Company, at least three (3) Business Days in advance, of its intent to impose any such
deduction or withholding, the basis therefor and the amounts thereof. 
 3.    Representations and
Warranties of the Company. The Company hereby represents and warrants to the Purchaser that, except as set forth in the Company SEC Documents (as defined herein), and only to the extent such Company SEC Documents are specifically referenced
in such representation or warranty, the following: 
 3.1    Organization, Good Standing and
Qualification. The Company is an entity duly incorporated, validly existing and in good standing under the Laws of the State of Delaware. The Company has all requisite corporate power and authority to own and operate its properties and assets,
to execute and deliver the Transaction Agreements, to issue and sell the Shares, and to carry out the provisions of the Transaction Agreements and to carry on its business as presently conducted and as presently proposed to be conducted. The Company
is not in violation or default of any of the provisions of its certificate of incorporation or bylaws. The Company is duly qualified to do business as a foreign entity and is in good standing (to the extent such concept exists in the relevant
jurisdiction) in each jurisdiction in which the conduct of its business or its ownership or leasing of property makes such qualification necessary, except to the extent any failure to so qualify has not had and would not reasonably be expected to
have a Material Adverse Effect. The Company has no subsidiaries. 
 3.2    Capitalization. 

(a)    The authorized capital of the Company, as of December 31, 2016, consists of 200,000,000 shares of Common
Stock, 21,501,842 of which are issued and outstanding, and 10,000,000 shares of preferred stock, par value $0.0001 per share, none of which are currently issued and outstanding. Under the Company’s 2010 Equity Incentive Plan and 2014 Equity
Incentive Plan (together, the “Plans”), (i) options to acquire 3,227,894 shares of Common Stock have been granted and are currently outstanding, (ii) no restricted shares of Common Stock have been granted and are currently
outstanding, and (iii) no shares of Common Stock remain available for future issuance to directors, executive officers, employees and consultants of the Company. Since December 31, 2016, the Company has not issued any equity securities, other than
those issued pursuant to the Plans. 

  
 8 

 (b)    Except as set forth in the Company SEC Documents filed prior
to the Signing Date, other than the shares of Common Stock reserved for issuance under the Plans, there are no outstanding options, rights (including conversion or preemptive rights and rights of first refusal), proxy or shareholder agreements, or
agreements of any kind for the purchase or acquisition from the Company of any of its securities, including the Shares. No Person is entitled to preemptive rights, rights of first refusal, rights of participation or similar rights with respect to
any securities of the Company, including with respect to the issuance of Shares contemplated hereby. Except as set forth in the Company SEC Documents filed prior to the Signing Date, there are no voting agreements, registration rights agreements or
other agreements of any kind between the Company and any other Person relating to the securities of the Company, including the Shares. 

(c)    All of the issued and outstanding shares of Common Stock have been duly authorized and validly issued and
are fully paid and were issued in compliance with all applicable Laws concerning the issuance of securities. The Shares have been duly and validly authorized and, when issued and paid for pursuant to this Agreement, (i) will be validly issued, and
fully paid, (ii) will not be subject to pre-emptive rights, and (iii) shall be free and clear of all Liens, except for restrictions on transfer imposed by (1) applicable securities Laws and (2) Section 5.10 hereunder. 

(d)    The Company does not own or hold the right to acquire any stock, partnership, interest, joint venture
interest or other equity ownership interest in any Person. 
 3.3    Authorization; Binding Obligations.
The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this Agreement and otherwise to carry out its obligations hereunder. The execution and delivery of this Agreement by the
Company and the consummation by it of the transactions contemplated hereby have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company, the Board of Directors or the Company’s
stockholders. Each of the Transaction Agreements has been duly executed and delivered by the Company and constitutes valid and binding obligations of the Company enforceable in accordance with their terms, except (a) as limited by applicable
bankruptcy, insolvency, reorganization, moratorium or other Laws of general application affecting enforcement of creditors’ rights, (b) general principles of equity that restrict the availability of equitable remedies and (c) to the extent that
the enforceability of indemnification provisions may be limited by applicable Laws. 
 3.4    Company SEC
Documents; Financial Statements; NASDAQ; Indebtedness. 
 (a)    Since October 1, 2014, the Company has
timely filed or submitted all required reports, schedules, forms, statements and other documents (including exhibits and all other information incorporated therein), and any required amendments to any of the foregoing, with the SEC pursuant to the
Exchange Act and the Securities Act (the “Company SEC 

  
 9 

 
Documents”). As of their respective filing or submission dates, each of the Company SEC Documents complied in all material respects with the requirements of the Securities Act
and Exchange Act applicable to such Company SEC Documents, and no Company SEC Documents when filed, declared effective or mailed, as applicable, contained any untrue statement of a material fact or omitted to state a material fact required to be
stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. As of the date hereof, there are no outstanding or unresolved comments in comment letters from the SEC
staff with respect to any of the Company SEC Documents and none of the Company SEC Documents is the subject of ongoing SEC review or outstanding investigation. The Company has never been an issuer subject to Rule 144(i) under the Securities Act.

 (b)    The financial statements of the Company included in the Company SEC Documents when filed complied as
to form in all material respects with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto, have been prepared in accordance with United States generally accepted accounting principles applied on
a consistent basis during the periods involved (“U.S. GAAP”), except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes
required by U.S. GAAP, and fairly present in all material respects the financial position of the Company as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited
statements, to normal, year-end audit adjustments. Except (i) as set forth in or contemplated by the Company SEC Documents filed prior to the Signing Date or (ii) for liabilities incurred in the ordinary course of business subsequent to the date of
the most recent balance sheet contained in the Company SEC Documents filed prior to the Signing Date, the Company has no liabilities, whether absolute or accrued, contingent or otherwise, other than those that would not, individually or in the
aggregate, be material to the Company. The Company does not have and is not subject to any “Off-Balance Sheet Arrangement” (as defined in Item 303(a)(4)(ii) of Regulation S-K promulgated under the Securities Act). 

(c)    The Common Stock is listed on the NASDAQ Global Select Market, and the Company has taken no action designed
to, or which would reasonably be expected to have the effect of, terminating the registration of the Common Stock under the Exchange Act or delisting the Common Stock from the NASDAQ Global Select Market. The Company has not received any
notification that, and has no Knowledge that, the SEC or NASDAQ is contemplating terminating such listing or registration. 

(d)    As of the date hereof, other than as disclosed in the Company SEC Documents filed prior to the Signing
Date, the Company does not have any outstanding Indebtedness. 
 3.5    Obligations to Related Parties.
Except as disclosed in the Company SEC Documents filed prior to the Signing Date, there are no obligations of the Company to members of the Board of Directors, executives, stockholders, Affiliates, or employees of the Company other than (a) for
payment of salary for services rendered, (b) reimbursement for reasonable expenses incurred on behalf of the Company, and (c) for other standard employee benefits made generally available to all employees (including equity award agreements
outstanding under any equity incentive plan approved by the Board of Directors). Except as 

  
 10 

 
disclosed in the Company SEC Documents filed prior to the Signing Date, none of the members of the Board of Directors, Affiliates, executives, employees or, to the Company’s Knowledge,
stockholders of the Company or any members of their immediate families, is indebted to the Company or has any direct or indirect ownership interest in any firm or corporation with which the Company is affiliated or with which the Company has a
business relationship, or any firm or corporation that competes with the Company, other than passive investments in publicly-traded companies (representing less than three percent (3%) of such company) which may compete with the Company and
investments by venture capital funds or similar institutional investors with which members of the Board of Directors may be affiliated. No member of the Board of Directors, executive, Affiliate or, to the Company’s Knowledge, stockholder, or
any member of their immediate families, is, directly or indirectly, interested in any Material Contract with the Company (other than such contracts as relate to any such person’s ownership of Common Stock or other securities of the Company).

 3.6    Compliance with Other Instruments. The Company is not in violation or default of any
provision of any mortgage, indenture, Contract, lease, agreement, instrument or Contract to which it is party or by which it is bound or of any Order which would reasonably be expected to have a Material Adverse Effect. The execution, delivery, and
performance of and compliance with the Transaction Agreements, and the issuance and sale of the Shares pursuant hereto, will not, with or without the passage of time or giving of notice, (i) conflict with or result in a violation of the certificate
of incorporation or bylaws of the Company, in each case as in effect on Closing Date, (ii) result in any violation of any Law or Order to which the Company or its assets is subject, (iii) (A) conflict with or result in a breach, violation of, or
constitute a default under, (B) give any third party the right to modify, terminate or accelerate, or cause any modification, termination or acceleration of, any obligation under, or (C) require Consent under, any Contract to which the Company is a
party, or (iv) result in the creation of any Lien upon any of the Company’s assets or capital stock, except in the case of any of clauses (ii), (iii) and (iv) above, as would not reasonably be expected to have a Material Adverse Effect. Neither
the execution, delivery or performance of any Transaction Agreement by the Company, nor the consummation by it of the obligations and transactions contemplated hereby and thereby (including the issuance of the Shares) requires any Consent, other
than (i) filings required under applicable U.S. federal and state securities Laws, (ii) the filing with the SEC of the Prospectus Supplement, and (iii) the notification of the issuance and sale of the Shares to NASDAQ. 

3.7    Litigation. There is no Action pending or, to the Company’s Knowledge, threatened,
against the Company or which the Company intends to initiate. There is no Order in effect against the Company. 

3.8    Compliance with Laws; Permits. The Company is not, and since January 1, 2014 has not been, in
violation of any applicable Law (including any Health Care Law) in respect of the conduct of its business or the ownership of its properties which would reasonably be expected to have a Material Adverse Effect. No Consents are required to be filed
in connection with the execution and delivery of this Agreement or the issuance of the Shares, except such as have been duly and validly obtained or filed. The Company has all franchises, permits, licenses and any similar authority necessary for the
conduct of its business as now being conducted by it, the lack of which would reasonably be expected to have a Material Adverse Effect, and believes it can obtain, without undue burden or expense, any similar authority for the conduct of its
business as currently planned to be conducted, the lack of which would reasonably be expected to have a Material Adverse Effect. 

  
 11 

 3.9    Registration. The Company has prepared and filed the
Registration Statement in conformity with the requirements of the Securities Act, which became effective on November 25, 2015, including the Base Prospectus, and such amendments and supplements thereto as may have been required to the date of
this Agreement. The Registration Statement is effective under the Securities Act and no stop order preventing or suspending the effectiveness of the Registration Statement or suspending or preventing the use of the Prospectus has been issued by the
SEC and no proceedings for that purpose have been instituted or, to the knowledge of the Company, are threatened by the SEC. At the time the Registration Statement and any amendments thereto became effective, at the date of this Agreement and
at the Closing Date, the Registration Statement and any amendments thereto conformed and will conform in all material respects to the requirements of the Securities Act and did not and will not contain any untrue statement of a material fact or omit
to state any material fact required to be stated therein or necessary to make the statements therein not misleading; and the Prospectus and any amendments or supplements thereto, at time the Prospectus or any amendment or supplement thereto was
issued and at the Closing Date, conformed and will conform in all material respects to the requirements of the Securities Act and did not and will not contain an untrue statement of a material fact or omit to state a material fact necessary in order
to make the statements therein, in light of the circumstances under which they were made, not misleading. 

3.10    Investment Company. The Company is not, and after giving effect to the transactions contemplated by
the Transaction Agreements will not be, an “investment company” or a company “controlled” by an “investment company,” within the meaning of the Investment Company Act of 1940, as amended. 

3.11    Sarbanes-Oxley; Internal Accounting Controls. The Company is in compliance with all applicable
requirements of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and all applicable rules and regulations promulgated by the SEC thereunder that are effective as of the date hereof. The Company qualifies as an “emerging
growth company” as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and has taken advantage of relief from certain reporting requirements and other burdens that are otherwise applicable generally to
public companies. The Company has taken the exemption from auditor attestation on the effectiveness of its internal controls over financial reporting as permitted under the JOBS Act. The Company maintains a system of internal accounting controls
sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with management’s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in
conformity with U.S. GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management’s general or specific authorization, and (iv) the recorded accountability for assets is compared with the
existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company has established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and
designed such disclosure controls and procedures to provide reasonable assurance that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported,
within the time periods specified in the SEC’s rules and forms. 

  
 12 

 3.12    Absence of Changes. Except as set forth in the Company
SEC Documents filed prior to the Signing Date, since December 31, 2015, (a) the Company has conducted its business operations in the ordinary course of business consistent with past practice and (b) there has not occurred any event, change,
development, circumstance or condition that, individually or in the aggregate, has had or would reasonably be expected to have a Material Adverse Effect. 

3.13    Tax Matters. 

(a)    Except as set forth in the Company SEC Documents filed prior to the Signing Date (i) the Company has timely
prepared and filed all federal and all other material Tax Returns required to have been filed by each of them with all appropriate Governmental Authorities and timely paid all Taxes shown thereon, (ii) all such Tax Returns are true, correct and
complete in all material respects, (iii) all Taxes that the Company is required to withhold or to collect for payment have been duly withheld and collected and paid to the proper Governmental Authority or third party when due, and (iv) no claim has
ever been made by a Governmental Authority in a jurisdiction where the Company does not file Tax Returns that the Company is or may be subject to taxation by that jurisdiction; 

(b)    Except as set forth in the Company SEC Documents filed prior to the Signing Date (i) no federal, state,
local, or non-U.S. Tax audits or administrative or judicial Tax proceedings are pending or being conducted with respect to the Company, (ii) the Company has not received from any federal, state, local, or non-U.S. taxing authority any (A) written
notice indicating an intent to open an audit or other review related to any material Tax, or (B) written notice of deficiency or proposed adjustment for any material amount of Tax proposed, asserted, or assessed by any taxing authority against the
Company; 
 (c)    Except as set forth in the Company SEC Documents filed prior to the Signing Date (i) the
Company (A) has not been a member of an affiliated group filing a consolidated federal income Tax Return or (B) does not have any liability for the Taxes of any Person (other than the Company) under U.S. Treas. Reg. § 1.1502-6 (or any similar
provision of state, local, or non-U.S. Law), as a transferee or successor, by Contract, or otherwise; 

(d)    The Company has not distributed stock of another Person, or has had its stock distributed by another
Person, in a transaction that was purported or intended to be governed in whole or in part by Section 355 or 361 of the Code; 

(e)    The Company is not and has not been a party to any “listed transaction,” as defined in Section
6707A(c)(2) of the Code and U.S. Treas. Reg. § 1.6011-4(b)(2); and 
 (f)    The Company has never been,
nor will it be at the Closing, a United States Real Property Holding Corporation within the meaning of Section 897(c)(2) of the Code during the applicable period specified in Section 897(c)(1)(A)(ii) of the Code. 

  
 13 

 3.14    Property. The Company does not own any real property.
Except as would not reasonably be expected to, individually or in the aggregate, have a Material Adverse Effect, (a) the Company has the right to use or occupy the Leased Real Property under valid and binding leases and (b) the Company has good and
valid title to, or a valid license to use or leasehold interest in, all of their respective material tangible assets, free and clear of all Liens (other than Permitted Liens). 

3.15    Employee Benefits Matters. 

(a)    Each Employee Benefit Plan (and each related trust, insurance Contract, or fund) has been maintained,
funded and administered in accordance with its terms and in compliance with the applicable requirements of Law, including ERISA and the Code and other applicable Laws, except where the failure to so maintain, fund or administer would reasonably be
expected to result in a Material Adverse Effect, and all contributions, distributions, reimbursements and premium payments due with respect to each Employee Benefit Plan have been timely made or properly accrued. Each Employee Benefit Plan that is
intended to meet the requirements of a “qualified plan” under Section 401(a) of the Code has received a favorable determination letter (or may rely on a favorable opinion letter) issued by the United States Internal Revenue Service and to
the Company’s Knowledge, nothing has occurred that would reasonably be expected to adversely affect the qualification of such Employee Benefit Plan. 

(b)    The Company does not maintain, sponsor, contribute to, have any obligation to contribute to, or have any
current or potential liability or obligation under or with respect to (i) a “defined benefit plan” (as such term is defined in Section 3(35) of ERISA), (ii) a “multiple employer plan” (within the meaning of Section 210 of ERISA
or Section 413(c) of the Code), or (iii) a “multiemployer plan” as defined in Section 3(37) of ERISA, or (iv) a “multiple employer welfare arrangement” (as such term is defined in Section 3(40) of ERISA); no Employee Benefit Plan
provides and the Company does not have any current or potential obligation to provide post-termination or post-retirement health, life or other welfare benefits other than as required under Section 4980B of the Code or any similar state Law; and the
Company does not have any current or potential liability or obligation by reason of at any time being treated as a single employer under Section 414 of the Code with any other Person. 

(c)    There have been no prohibited transactions (as defined in Section 406 of ERISA or Section 4975 of the Code)
and no breach of fiduciary duty (as determined under ERISA) with respect to any Employee Benefit Plan; the Company has, for purposes of each Employee Benefit Plan, correctly classified those individuals performing services for the Company as
employees or non-employees; and there do not exist any pending or, to the Company’s Knowledge, threatened claims (other than routine undisputed claims for benefits) or Actions with respect to any Employee Benefit Plan. 

(d)    The transactions contemplated by the Transaction Agreements will not (either alone or in combination with
another event) (i) cause the acceleration of vesting in, or payment of, any benefits or compensation under any Employee Benefit Plan, (ii) require the funding of compensation or benefits due to any manager, employee, officer, director, shareholder
or other service provider (whether current, former or retired) of the Company or their beneficiaries and, (iii) otherwise accelerate or increase any liability or obligation under any Employee Benefit Plan. 

  
 14 

 3.16    Labor Matters. 

(a)    The Company is not a party to nor is bound by any collective bargaining agreement or other Contract or
relationship with any union, labor organization, or other collective bargaining representative. There are no strikes, work stoppages or any other material labor disputes against or affecting the Company pending or, to the Company’s Knowledge,
threatened, and no such disputes have occurred since January 1, 2014. No union organization or decertification activities are underway or, to the Company’s Knowledge, threatened with respect to employees of the Company and no such activities
have occurred since January 1, 2014. 
 (b)    The Company is, and at all times since January 1, 2014 has been,
in compliance in all material respects with all applicable Laws respecting employment and employment practices, including provisions thereof relating to terms and conditions of employment, wages and hours, overtime, classification of employees and
independent contractors, immigration, and the withholding and payment of social security and other employment Taxes, except where the failure to be in such compliance would reasonably be expected to have a Material Adverse Effect.. 

(c)    Since January 1, 2014, the Company has not implemented any plant closing or layoff of employees that could
implicate the WARN Act. 
 3.17    Intellectual Property. 

(a)    The Company owns all right, title and interest in and to, or has the valid and enforceable right to use
pursuant to a written Contract, all Intellectual Property used in the conduct of the business of the Company as currently conducted or proposed to be conducted (collectively, the “Company Intellectual Property”) free and clear of
any Liens, except Permitted Liens, except where the failure to be in such compliance would reasonably be expected to have a Material Adverse Effect, and, to the Company’s Knowledge, the owners of any Intellectual Property licensed to Company
have taken necessary actions to maintain and protect such Intellectual Property, except where the failure to be in such compliance would reasonably be expected to have a Material Adverse Effect. 

(b)    The Company has not infringed, misappropriated, or otherwise violated, or is not currently infringing,
misappropriating, or otherwise violating, any Intellectual Property of any other Person and there are no Actions pending or, to the Company’s Knowledge, threatened alleging any of the foregoing, including any unsolicited offers for the Company
to obtain a license to any Intellectual Property of another Person. To the Company’s Knowledge, no Person is infringing, misappropriating or violating the rights of the Company with respect to any Company Intellectual Property. 

(c)    The Company has taken commercially reasonable steps to maintain and protect the secrecy and confidentiality
of its material confidential information. Without limiting the generality of the foregoing, all current and former employees, contractors and 

  
 15 

 
consultants of the Company who have participated in the creation of Intellectual Property have executed and delivered to the Company a valid and enforceable agreement providing for the assignment
by such Person to the Company of any such Intellectual Property.
 3.18    Environmental Matters. Except
as would not reasonably be expected to, individually or in the aggregate, have a Material Adverse Effect: (i) no notice, notification, demand, request for information, citation, summons, complaint or Order has been received within the past three
years by, and no Action is pending or, to the Company’s Knowledge, threatened by, any Person against the Company and no penalty has been assessed against the Company with respect to any matters relating to or arising out of any Environmental
Law and (ii) the Company is, and since January 1, 2014 has been, in compliance with all applicable Environmental Laws, including any Consent required by Environmental Laws. 

3.19    Brokers and Finders. No Person will have, as a result of the transactions contemplated by the
Transaction Agreements, any right, interest or claim against or upon the Company for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of the Company. The Company agrees to
indemnify the Purchaser for any claims, losses or expenses incurred by the Purchaser as a result of the representation in this Section 3.19 being untrue. 

3.20    Insurance. Except as has not had, and would not reasonably be expected to have, individually
or in the aggregate, a Material Adverse Effect, (a) all insurance policies (“Policies”) with respect to the business and assets of the Company are in full force and effect, (b) the Company is not in breach or default, and the
Company has not taken any action or failed to take any action that, with notice or the lapse of time, would constitute such a breach or default, or permit termination or modification of any of the Policies, and (c) the Company has not received any
written notice of cancellation or threatened cancellation of any of the Policies or of any claim pending regarding the Company under any of such Policies as to which coverage has been questioned, denied or disputed by the underwriters of such
Policies. The Company maintains insurance with reputable insurers in such amounts and against such risks as is customary for the industry in which the Company operates and as the management of the Company has in good faith determined to be prudent
and appropriate. 
 3.21    Contracts. Except as would not reasonably be expected to have, individually or
in the aggregate, a Material Adverse Effect, the Company is not in violation, default or breach under any of its Material Contracts. All Material Contracts have been filed with the Company SEC Documents. 

3.22    Application of Takeover Protections. The Company and the Board of Directors have taken all necessary
action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar anti-takeover provision under the Company’s certificate of
incorporation or the Laws of the State of Delaware that is or could become applicable to the Purchaser as a result of the Purchaser and the Company fulfilling their obligations or exercising their rights under this Agreement, including without
limitation as a result of the Company’s issuance of the Shares and the Purchaser’s ownership of the Shares. 

  
 16 

 3.23    Anti-Corruption and Anti-Bribery Laws. Neither the
Company, nor, any of its officers, directors or employees, nor to the Company’s Knowledge its agents, representatives, consultants, or other persons associated with or acting for or on behalf of the Company, has, directly or indirectly, in
connection with the operation of their business: (a) made, offered or promised to make or offer any payment, loan or transfer of anything of value, including any reward, advantage or benefit of any kind, to or for the benefit of any government
official, candidate for public office, political party or political campaign, for the purpose of (i) influencing any act or decision of such government official, candidate, party or campaign, (ii) inducing such government official, candidate, party
or campaign to do or omit to do any act in violation of a lawful duty, (iii) obtaining or retaining business for or with any person, (iv) expediting or securing the performance of official acts of a routine nature, or (v) otherwise securing any
improper advantage, in each case, in violation of any applicable anticorruption or anti-bribery Law, (b) paid, offered or promised to pay or offer any bribe, payoff, influence payment, kickback, unlawful rebate, or other similar unlawful payment of
any nature, (c) made, offered or promised to make or offer any unlawful contributions, gifts, entertainment or other unlawful expenditures, (d) established or maintained any unlawful fund of corporate monies or other properties, (e) created or
caused the creation of any false or inaccurate books and records of the Company related to any of the foregoing, or (f) otherwise violated any provision of the Foreign Corrupt Practices Act of 1977, 15 U.S.C. §§ 78dd-l, et seq., or any
other applicable anti-corruption or anti-bribery Law. For purposes of this provision, “government official” includes any officer or employee of a government or any department, agency or instrumentality thereof (including wholly or
partially owned enterprises or institutions), or of a public international organization, or any person acting in an official capacity for or on behalf of any such government or department, agency or instrumentality, or for or on behalf of any such
public international organization. 
 3.24    Economic Sanctions. None of the Company or its directors,
officers, employees or to the Company’s Knowledge its agents (i) is a person with whom transactions are prohibited or limited under any applicable economic sanctions Laws or (ii) within the last five (5) years has done business in or with any
Person that is the target of sanctions by the United States. Within the past five (5) years, the Company has not made any voluntary disclosures to applicable Governmental Authorities under applicable economic sanctions Laws or applicable export
control Laws and, to the Knowledge of the Company, the Company has not been the subject of any governmental investigation or inquiry regarding the compliance of the Company with such Laws, nor has the Company been assessed any fine or penalty in
regard to compliance with such Laws. 
 3.25    Accountants. The Company’s independent registered
public accounting firm is Ernst & Young LLP. To the Company’s Knowledge, such accounting firm is a registered public accounting firm as required by the Exchange Act. 

3.26    Money Laundering. The operations of the Company are and have been conducted at all times in
compliance with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable money laundering statutes and applicable rules and regulations thereunder
(collectively, the “Money Laundering Laws”), and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company with respect to the Money Laundering Laws is
pending or, to the Company’s Knowledge, threatened. 

  
 17 

 3.27    Disclosure. None of the representations or warranties
in this Article III nor any of the exhibits or schedules attached hereto, nor any of the certificates delivered pursuant to Section 6.1, contain any untrue statement of a material fact or omit a material fact necessary to make each statement
contained herein or therein, in light of the circumstances in which they were made, not misleading. 

4.    Representations and Warranties of the Purchaser. The Purchaser
hereby represents and warrants to the Company as follows: 
 4.1    Organization; Good Standing. The
Purchaser is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware. The Purchaser has all requisite power and authority to enter into the Transaction Agreements, to purchase the Shares and to
perform its obligations under and to carry out the other transactions contemplated by the Transaction Agreements. 

4.2    Requisite Power and Authority. The Purchaser has all necessary power and authority to execute and
deliver the Transaction Agreements and to carry out their provisions. All action on the Purchaser’s part required for the lawful execution and delivery of the Transaction Agreements has been taken. Upon their execution and delivery, the
Transaction Agreements will be valid and binding obligations of the Purchaser, enforceable in accordance with their terms, except (a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium or other Laws of general
application affecting enforcement of creditors’ rights, (b) as limited by general principles of equity that restrict the availability of equitable remedies, and (c) to the extent that the enforceability of indemnification provisions
may be limited by applicable Laws. 
 4.3    No Conflicts. The execution, delivery and performance of the
Transaction Agreements and compliance with the provisions thereof by the Purchaser do not and shall not: (a) violate any provision of applicable Law or any ruling, writ, injunction, order, permit, judgment or decree of any Governmental Authority,
(b) constitute a breach of, or default under (or an event which, with notice or lapse of time or both, would become a default under) or conflict with, or give rise to any right of termination, cancellation or acceleration of, any agreement,
arrangement or instrument, whether written or oral, by which the Purchaser or any of its assets, are bound, or (c) violate or conflict with any of the provisions of the Purchaser’s certificate of incorporation or bylaws, except as would not
impair or adversely affect the ability of the Purchaser to consummate the transactions contemplated pursuant to the Transaction Agreements and perform its obligations under the Transaction Agreements and except, in the case of subsections (a) and
(b) as would not have a material adverse effect on the Purchaser. 
 4.4    No Governmental Authority or Third
Party Consents. No Consent is required to be obtained by the Purchaser in connection with the authorization, execution and delivery of any of the Transaction Agreements or with the subscription for the Shares. 

  
 18 

 4.5    Investment Representations. The Purchaser hereby
represents and warrants as follows: 
 (a)    Purchaser Bears Economic Risk. The Purchaser has
substantial experience in evaluating and investing in private placement transactions of securities in companies similar to the Company and is capable of evaluating the merits and risks of its investment in the Company and has the capacity to protect
its own interests.
 (b)    Acquisition for Own Account. The Purchaser is acquiring the Shares for the
Purchaser’s own account for investment only, and not with a view towards their distribution. 

(c)    Accredited Investor. The Purchaser represents that it is an accredited investor within the meaning
of Regulation D under the Securities Act. 
 (d)    Company Information. The Purchaser has had an
opportunity to discuss the Company’s business, management and financial affairs with management of the Company. The Purchaser has also had the opportunity to ask questions of, and receive answers from, the Company and its management regarding
the terms and conditions of this investment. The foregoing does not affect the Company’s representations and warranties contained in Section 3. 

4.6    Transfer Restrictions. The Purchaser acknowledges that the Shares will be subject to a transfer
restriction under Section 5.10 below. 
 5.    Covenants and Agreements. 

5.1    Further Assurances. Subject to the terms and conditions of this Agreement, each of the Company
and the Purchaser agrees to use its reasonable best efforts to take, or cause to be taken, all actions, and to do, or cause to be done, and assist the other party hereto in doing, all things reasonably necessary, proper or advisable to obtain
satisfaction of the conditions precedent to the consummation of the transactions contemplated at the Closing: (a) obtaining all necessary Consents and the making of all filings and the taking of all steps as may be necessary to obtain Consent
from, or to avoid an Action by, any Governmental Authority, (b) the defending of any Actions challenging this Agreement or any other Transaction Agreements or the consummation of the transactions contemplated hereby or thereby, including seeking to
have any stay or temporary restraining order entered by any court or other Governmental Authority vacated or reversed, and (c) the execution and delivery of any additional instruments necessary to consummate the transactions contemplated by, and to
fully carry out the purposes of, this Agreement and the other Transaction Agreements. 
 5.2    Non-Public
Information. Except as contemplated by the Collaboration Agreement, the Company covenants and agrees that neither it, nor any other Person acting on its behalf will provide Purchaser or its agents or counsel with any information that constitutes
material non-public information, unless prior thereto Purchaser shall have entered into a written agreement with the Company regarding the confidentiality and use of such information. The Company understands and confirms that Purchaser will be
relying on the foregoing covenant in effecting transactions in securities of the Company. 

  
 19 

 5.3    No Restrictions on Transfer. Subject to
restrictions on transfer imposed by applicable securities Laws and Section 5.10 below, the Shares shall be freely transferrable. 

5.4    Securities Law Disclosure; Publicity. No public release or announcement concerning the
transactions contemplated hereby or by any other Transaction Agreement, including the public filing of any Transaction Agreement pursuant to applicable securities Laws, shall be issued by the Company or the Purchaser without the prior consent of the
Company (in the case of a release or announcement by the Purchaser) or the Purchaser (in the case of a release or announcement by the Company) (which consents shall not be unreasonably withheld, conditioned or delayed), except for any such public
filing, release or announcement as may be required by securities Law or other applicable Law or the applicable rules or regulations of any securities exchange or securities market, in which case the Company or the Purchaser, as the case may be,
shall allow the Purchaser or the Company, as applicable, reasonable time to comment on such public filing, release or announcement in advance of such filing or issuance and the disclosing party shall consider the other party’s comments in good
faith. Following the execution and delivery of this Agreement, the Company and the Purchaser shall issue a joint press release substantially in the form attached to the Collaboration Agreement as Exhibit 13.3(a). 

5.5    NASDAQ Matters. Prior to the Closing, the Company shall (a) take all actions which are
necessary, including providing appropriate notice to NASDAQ of the transactions contemplated by this Agreement, for the Shares purchased at the Closing to remain listed on the NASDAQ Global Select Market and (b) comply with all listing, reporting,
filing, and other obligations under the rules of NASDAQ and of the SEC. 
 5.6    Interim Operations of the
Company. Prior to the Closing Date or the earlier termination of this Agreement in accordance with its terms, the Company shall not voluntarily delist from the NASDAQ Global Select Market. Between the date hereof and the Closing Date, the
Company will not amend its certificate of incorporation or bylaws in a manner that is adverse to the Purchaser’s rights under the Transaction Agreements, and will not take or omit to take any action that would or could reasonably be expected to
have a Material Adverse Effect. 
 5.7    Integration. The Company shall not sell, offer for sale or
solicit offers to buy or otherwise negotiate in respect of any security (as defined in the Securities Act) that would be integrated with the offer or sale of the Shares to be issued to the Purchaser hereunder for purposes of the rules and
regulations of any of the following markets or exchanges on which the Common Stock or the Company is listed or quoted for trading on the date in question: the Pink OTC Markets, the OTC Bulletin Board, the NASDAQ Capital Market, the NASDAQ Global
Market, the NASDAQ Global Select Market, the NYSE MKT or the New York Stock Exchange. 

5.8    Notification. After the date hereof and prior to the Closing Date, the Company
shall promptly deliver to the Purchaser a written notice of any event or development that would, or could reasonably be expected to, result in any condition to Closing set forth in Section 6, not to be satisfied. 

  
 20 

 5.9    Use of Proceeds. The net proceeds received by the
Company from each Closing shall be used for general corporate purposes at the direction of the Board of Directors. 

5.10    “Lock-Up” Agreement; Confidentiality of Notices. 

(a)    The Purchaser agrees not to (a) offer, pledge, announce the intention to sell, sell, contract to sell, sell
any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any Shares or other securities of the Company or (b) enter into
any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of any Shares or other securities of the Company (in each case, a “Transfer”), whether any transaction described in
clause (a) or (b) is to be settled by delivery of securities, in cash or otherwise, during the period beginning on the Signing Date and continuing through the close of trading 180 days from the Closing Date. Notwithstanding this Section 5.10(a), the
Purchaser shall be permitted to Transfer any portion or all of its Shares or other securities of the Company at any time under the following circumstances: 

(i)    Transfers to any Affiliate, but only if the transferee agrees in writing for the benefit of the Company (in
form and substance satisfactory to the Company and with a copy thereof to be furnished to the Company) to be bound by the terms of this Agreement; or 

(ii)    Transfers that have been approved in writing by the Company. 

(b)    From the date hereof until the termination of the Purchaser’s right to participate in Subsequent
Financings (as defined below), if the Purchaser then owns at least five percent (5%) of the Company’s outstanding voting securities, the Purchaser will execute and promptly deliver any lock-up agreement as may be requested by the Company or the
managing underwriter(s) or placement agent(s), as the case may be, in connection with a Subsequent Financing following the Closing Date. The Company shall deliver the form of requested lock-up agreement to the Purchaser at least five (5) Trading
Days prior to the closing of the Subsequent Financing, but in no event sooner than the date that the Company, or the managing underwriter(s) or placement agent(s), as the case may be, solicit indications of interest from potential investors in a
Subsequent Financing. The Purchaser will have no obligations under this Section 5.10(b), unless the managing underwriter(s) or placement agent(s), as the case may be, have requested and received a lock-up agreement from: (i) all executive officers
and directors of the Company and (ii) all Affiliates of the Company who are also holders of at least five percent (5%) of the Company’s voting securities. Such lock-up agreement shall be on substantially similar terms with no material
difference in terms and conditions from those executed by the parties set forth in (i) and (ii) in the preceding sentence, and in no event shall such lock-up agreement restrict the Purchaser for a period longer than ninety (90) days after the date
of the final prospectus related to such Public Offering (as defined below), or the date of the purchase agreement related to the Private Offering (as defined below) as the case may be. Such lock-up agreement shall terminate if the underwriting
agreement or the purchase agreement, as the case may be, related to the Subsequent Financing, is not executed with thirty (30) days of the date of such lock-up agreement.

  
 21 

 (c)    The Purchaser acknowledges that the Company shall impose
stop-transfer instructions with respect to the Shares subject to the restriction set forth in Section 5.10(b) until the end of such “lock-up” period. 

(d)    If the Purchaser receives any notice from the Company regarding the Company’s plans to conduct a
Subsequent Financing, the Purchaser shall treat such notice as Confidential Information (as such term is defined in the Collaboration Agreement). 

5.11    Participation in Future Financing. 

(a)    Subject to compliance with applicable securities laws, from the date hereof until the earlier of (i) the
second anniversary of the Signing Date or (ii) expiration of the Term (as such term is defined in the Collaboration Agreement), upon (i) any issuance by the Company of un-registered shares of Common Stock or Common Stock Equivalents (a
“Private Offering”) or (ii) any issuance by the Company of registered shares of Common Stock or Common Stock Equivalents (a “Public Offering” and together with the Private Offering, a “Subsequent
Financing”), in each case for cash consideration, indebtedness or a combination thereof, then for a Private Offering the Purchaser shall have the right to participate, and with respect to a Public Offering the Company shall use commercially
reasonable efforts (which must include multiple attempts, on multiple dates, with multiple representatives of the managing underwriter(s), to cause the managing underwriter(s) of the Public Offering, or the placement agent(s) of the Private
Offering, to allow the Purchaser to submit an indication of interest in an amount of the Subsequent Financing up to the Purchaser’s Pro-Rata Share (as defined below) on the same terms, conditions and price provided for in the Subsequent
Financing. For purposes of this Agreement, the Purchaser’s “Pro-Rata Share” shall be equal to the lesser of (i) number of shares of Common Stock deemed to be beneficially owned by the Purchaser immediately prior to the closing
of the Subsequent Financing (based upon documentation or written representation reasonably satisfactory to the Company), divided by the total number of shares of Common Stock outstanding (including any shares of Common Stock issuable upon conversion
or exercise of outstanding Common Stock Equivalents deemed to be beneficially owned by the Purchaser and included in the numerator) immediately prior to the closing of the Subsequent Financing or (ii) the number of shares of Common Stock that would
result in Purchaser beneficially owning 19.99% of the outstanding shares of Common Stock of the Company.

(b)    At least five (5) Trading Days prior to the closing of a Public Offering, or at least ten (10) Trading Days
prior to the closing of a Private Offering, as applicable, but in no event sooner than the date that the Company, or the managing underwriter(s) or placement agent(s), as the case may be, solicit indications of interest from potential investors in a
Subsequent Financing, the Company shall deliver to the Purchaser notice of its intention to effect a Subsequent Financing (the “Subsequent Financing Notice”). In the event of a Private Offering, the Subsequent Financing Notice
shall be written and describe in reasonable detail the proposed terms of such Subsequent Financing, the amount of proceeds intended to be raised thereunder and the name and contact information of the placement agent(s) for such Private Offering and
shall include a term sheet or similar document relating thereto as an attachment. In the event of a Public Offering, the Subsequent Financing Notice shall be verbal and may at the election of the Company upon the advice of counsel be confirmed as
delivered in writing. The Purchaser acknowledges that in no event will the Company be required 

  
 22 

 
to deliver any Subsequent Financing Notice which upon the advice of counsel would be required to be filed as a free writing prospectus with the SEC or which could otherwise be deemed a violation
of Section 5 of the Securities Act. 
 (c)    If the Purchaser desires to participate in such Subsequent
Financing, the Purchaser must provide with respect to a Private Offering a written notice to the Company or with respect to a Public Offering a verbal indication of interest to the managing underwriter(s) by not later than 5:30 p.m. (New York City
time) on the second (2nd) Trading Day after Purchaser has received a Subsequent Financing Notice, that the Purchaser is willing to participate in the Subsequent Financing and stating the amount of the Purchaser’s elected participation. If the
Company or the managing underwriter(s) receive no such notice from the Purchaser as of such third (3rd) Trading Day, the Purchaser shall be deemed to have notified the Company that it does not elect to participate in the Subsequent Financing. In the
event that the Purchaser elects, or is deemed to have elected, not to purchase its full Pro Rata Share in the Subsequent Financing, the Purchaser will thereafter have no further right to participate in any future Subsequent Financing. If with
respect to a Public Offering, the Purchaser submits an indication of interest to purchase its full Pro Rata Share, and is not allocated its full Pro Rata Share by the managing underwriter(s), then Purchaser will retain its right to participate in
future Subsequent Financings.
 (e)    Notwithstanding anything to the contrary in this Section 5.12 and unless
otherwise agreed to by the Purchaser, in the event the Company determines to abandon a Subsequent Financing, the Company shall cause the managing underwriter(s) or placement agent(s), as the case may be, to confirm such abandonment to the Purchaser
in the same manner and on the same day as such abandonment is communicated to other potential investors. If, by the twentieth (20th) day following delivery of the Subsequent Financing Notice, no
public disclosure regarding a transaction with respect to the Subsequent Financing has been made, such Subsequent Financing shall be deemed to have been abandoned and the Purchaser shall not be in possession of any material, non-public information
with respect to the Company, unless the Company advises the Purchaser that the Subsequent Financing has not been abandoned. The Company understands and confirms that the Purchaser may rely on this Section 5.11(e) when effecting transactions in
securities of the Company. 
 (d)    Notwithstanding the foregoing, this Section 5.11 shall not apply in respect
of an Exempt Issuance. 
 (e)    Purchaser further agrees to execute such other documents and agreements as may
reasonably be requested of Purchaser by the managing underwriter(s) or placement agent(s), as the case may be, in connection with a Subsequent Financing. 

5.12    Subsequent Equity Sales. From the Signing Date until the Closing Date, the Company shall not
initiate any drawdowns or sales under the Common Stock Sales Agreement dated November 9, 2015 between the Company and Cowen and Company, LLC. 

  
 23 

 6.    Conditions to Closing. 

6.1    Conditions to Purchaser’s Obligations at the Closing. The Purchaser’s
obligation to purchase the Shares at the Closing is subject to the satisfaction, at or prior to the Closing Date, of the following conditions (unless waived in writing by the Purchaser): 

(a)    Representations and Warranties. The representations and warranties made by the Company in Section 3
hereof shall be true and correct in all material respects as of the date hereof and as of the Closing Date as if made on such date, except to the extent such representation and warranty is (i) specifically made as of a particular date, in which case
such representations and warranties shall be true and correct as of such date or (ii) already qualified by materiality, in which case it shall be true and correct as of such dates. 

(b)    Performance of Obligations. The Company shall have performed and complied with all agreements and
conditions herein required to be performed or complied with by the Company on or before the Closing Date. 

(c)    Legal Investment. The sale and issuance of the Shares shall be legally permitted by all Laws to
which the Purchaser and the Company are subject. 
 (d)    No Orders. No Order shall be in effect
preventing the consummation of the transactions contemplated by the Transaction Agreements. 
 (e)    Closing
Deliverables. The Company shall deliver or cause to be delivered to the Purchaser all items listed in Section 2.3(a). 

(f)    Collaboration Agreement. The Company shall have executed the Collaboration Agreement, the only
remaining condition to the effectiveness of the Collaboration Agreement shall be the Closing, the Effective Date (as such term is defined in the Collaboration Agreement) of the Collaboration Agreement shall have occurred, no breach by the Company of
any term of or obligation under the Collaboration Agreement shall have occurred and be continuing, and the Collaboration Agreement shall not have been terminated in accordance with its terms. 

(g)    Consents, Permits, and Waivers. All Consents necessary or appropriate for consummation of the
transactions contemplated by the Transaction Agreements shall have been obtained, including the approval of the Board of Directors.

(h)    Material Adverse Effect. No Material Adverse Effect shall have occurred and be continuing. 

(i)    The Company’s NASDAQ Listing. The Company’s Common Stock shall continue to be listed on
the NASDAQ Global Select Market. 
 6.2    Conditions to Company’s Obligations at the
Closing. The Company’s obligation to issue and sell Shares at the Closing is subject to the satisfaction, on or prior to the Closing Date, of the following conditions (unless waived in writing by the Company): 

  
 24 

 (a)    Representations and Warranties. The representations and
warranties in Section 4 made by the Purchaser shall be true and correct in all material respect as of the Closing Date. 

(b)    Performance of Obligations. The Purchaser shall have performed and complied with all agreements and
conditions herein required to be performed or complied with by the Purchaser on or before the Closing Date. 

(c)    Legal Investment. The sale and issuance of the Shares shall be legally permitted by all Laws to
which the Purchaser and the Company are subject. 
 (d)    No Orders. No Order shall be in effect
preventing the consummation of the transactions contemplated by the Transaction Agreements. 
 (e)    Closing
Deliverables. The Purchaser shall deliver or cause to be delivered to the Company all items listed in Section 2.3(b). 

(f)    Collaboration Agreement. The Collaboration Agreement shall not have been terminated in accordance
with its terms. 
 (g)    Consents, Permits, and Waivers. All Consents necessary or appropriate for
consummation of the transactions contemplated by the Transaction Agreements shall have been obtained. 

7.    Miscellaneous. 

7.1    Termination. This Agreement and the obligations of the parties hereunder may be terminated by: 

(a)    the Company and the Purchaser, by providing mutual written consent to terminate; 

(b)    either the Company or the Purchaser, upon written notice to the other no earlier than three (3) Trading
Days after February 3, 2017 (the “Original Termination Date”), if the Original Termination Date cannot be or has not been validly extended pursuant to this Section 7.1(b), and if the Closing shall not have been consummated by the
Original Termination Date; provided, however, that the Original Termination Date may be extended to February 10, 2017 (the “Final Termination Date”) by either the Company or the Purchaser, in their sole discretion, upon written
notice to the other on or within five (5) Trading Days prior to the Original Termination Date, if the Closing Date shall not have been consummated by the Original Termination Date solely as the result of a failure to satisfy the condition set forth
in Sections 6.1(g) and 6.2(g) as of the Original Termination Date; provided further, however, that the right to terminate this Agreement under this Section 7.1(b) shall not be available to any party whose failure to fulfill any obligation under this
Agreement has been the cause of, or resulted in, the failure to consummate the Closing prior to the Original Termination Date or the Final Termination Date, as applicable; 

  
 25 

 (c)    the Company if (i) any of the representations and warranties
of the Purchaser contained in Section 4 of this Agreement shall fail to be true and correct or (ii) there shall be a breach by the Purchaser of any covenant of the Purchaser in this Agreement that, in either case, (A) would result in the failure of
a condition set forth in Section 6.1, and (B) which is not curable or, if curable, is not cured upon the occurrence of the twentieth (20th) calendar day after written notice thereof is given the
Company to the Purchaser; 
 (d)    the Purchaser if (i) any of the representations and warranties of the
Company contained in Section 3 of this Agreement shall fail to be true and correct or (ii) there shall be a breach by the Company of any covenant of the Company in this Agreement that, in either case, (A) would result in the failure of a condition
set forth in Section 6.2, and (B) which is not curable or, if curable, is not cured upon the occurrence of the twentieth (20th) calendar day after written notice thereof is given by the Purchaser
to the Company; or 
 (e)    the Company or the Purchaser, upon notice to the other, if there shall be any Law
that makes consummation of the transactions contemplated by this Agreement illegal or otherwise prohibited, or a Governmental Authority of competent jurisdiction has issued an Order permanently enjoining or otherwise prohibiting or restraining the
consummation of the transactions contemplated by this Agreement, and such Order has become final and non-appealable; provided, however, that the right to terminate this Agreement pursuant to this Section 7.1(e) shall not be available to any
party whose breach of any provision of this Agreement results in or causes such Order or who is not in compliance with its obligations under Section 5. 

(f)    In the event of termination of this Agreement pursuant to Section 7 by either Purchaser or the Company,
this Agreement will become void and have no further force or effect, without any liability or obligation of the Purchaser, other than as set forth in Sections 5.3 and Article VII, which will each survive any termination of this Agreement. 

7.2    Governing Law; Waiver of Jury Trial. This Agreement shall be governed by and construed
in accordance with the Laws of the State of New York, without regard to the conflict of laws principles thereof that would require the application of the Law of any other jurisdiction. The parties irrevocably and unconditionally submit to the
exclusive jurisdiction of the United States District Court for the Southern District of New York solely and specifically for the purposes of any action or proceeding arising out of or in connection with this Agreement. EACH OF THE PARTIES TO THIS
AGREEMENT HEREBY AGREES THAT JURISDICTION AND VENUE IN ANY SUIT, ACTION OR PROCEEDING BROUGHT BY ANY PARTY ARISING OUT OF OR RELATING TO THIS AGREEMENT (INCLUDING ANY SUIT, ACTION OR PROCEEDING SEEKING EQUITABLE RELIEF) SHALL PROPERLY AND
EXCLUSIVELY LIE IN THE STATE AND FEDERAL COURTS LOCATED IN THE STATE OF NEW YORK (THE “CHOSEN COURTS”). EACH PARTY HERETO FURTHER AGREES NOT TO BRING ANY SUCH SUIT, ACTION OR PROCEEDING IN ANY COURT OTHER THAN THE CHOSEN COURTS
PURSUANT TO THE FOREGOING SENTENCE (OTHER THAN UPON APPEAL). BY EXECUTION AND DELIVERY OF THIS AGREEMENT, EACH PARTY IRREVOCABLY SUBMITS TO THE JURISDICTION OF THE CHOSEN COURTS FOR ITSELF AND IN RESPECT OF ITS PROPERTY WITH RESPECT TO SUCH SUIT,
ACTION OR PROCEEDING. THE PARTIES 

  
 26 

 
HERETO IRREVOCABLY AGREE THAT VENUE WOULD BE PROPER IN EACH OF THE CHOSEN COURTS, AND HEREBY WAIVE ANY OBJECTION THAT ANY SUCH CHOSEN COURT IS AN IMPROPER OR INCONVENIENT FORUM FOR THE RESOLUTION
OF SUCH SUIT, ACTION OR PROCEEDING. TO THE EXTENT NOT PROHIBITED BY APPLICABLE LAW WHICH CANNOT BE WAIVED, EACH PARTY HERETO HEREBY WAIVES AND COVENANTS THAT IT WILL NOT ASSERT (WHETHER AS PLAINTIFF, DEFENDANT OR OTHERWISE) ANY RIGHT TO TRIAL BY
JURY IN ANY FORUM IN RESPECT OF ANY ISSUE OR ACTION, CLAIM, CAUSE OF ACTION OR SUIT (IN CONTRACT, TORT OR OTHERWISE) INQUIRY, PROCEEDING OR INVESTIGATION ARISING OUT OF OR BASED UPON THIS AGREEMENT OR THE SUBJECT MATTER HEREOF OR IN ANY WAY
CONNECTED WITH OR RELATED OR INCIDENTAL TO THE TRANSACTIONS CONTEMPLATED HEREBY, IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING. EACH PARTY HERETO ACKNOWLEDGES THAT IT HAS BEEN INFORMED BY THE OTHER PARTIES HERETO THAT THIS SECTION 7.2
CONSTITUTES A MATERIAL INDUCEMENT UPON WHICH THEY ARE RELYING AND WILL RELY IN ENTERING INTO THIS AGREEMENT. ANY PARTY HERETO MAY FILE AN ORIGINAL COUNTERPART OR A COPY OF THIS SECTION 7.2 WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF EACH
SUCH PARTY TO THE WAIVER OF ITS RIGHT TO TRIAL BY JURY. 
 7.3    Survival. The representations,
warranties, covenants and agreements made herein shall survive the Closing. The representations, warranties, covenants and obligations of the Company, and the rights and remedies that may be exercised by the Purchaser, shall not be limited or
otherwise affected by or as a result of any information furnished to, or any investigation made by or knowledge of, the Purchaser or its representatives. 

7.4    Successors and Assigns. Except as otherwise expressly provided herein, the provisions hereof
shall inure to the benefit of, and be binding upon the parties hereto and their respective successors, assigns, heirs, executors and administrators and shall inure to the benefit of and be enforceable by each person who shall be a holder of the
Shares from time to time; provided, however, that prior to the receipt by the Company of adequate written notice of the transfer of any Shares specifying the full name and address of the transferee, the Company may deem and treat the person listed
as the holder of such Shares in its records as the absolute owner and holder of such Shares for all purposes. This Agreement may not be assigned by any party hereto without the consent of the other party, provided, that the Purchaser may assign its
rights and obligations hereunder in whole or in part to any Affiliate of the Purchaser or to any successor of the Purchaser as a result of a Change of Control of the Purchaser, provided that in the case of such assignment the Purchaser shall not be
relieved of its obligations hereunder, or to any transferee to whom Shares are properly transferred after the Closing pursuant to the terms of the Transaction Agreements. 

7.5    Entire Agreement. This Agreement, the exhibits and schedules hereto, the other Transaction
Agreements, and the other documents delivered pursuant hereto constitute the full and entire understanding and agreement between the parties with regard to the subjects hereof and no party shall be liable for or bound to any other in any manner by
any oral or written representations, warranties, covenants and agreements except as specifically set forth herein and therein. 

  
 27 

 7.6    Severability. In the event one or more of the
provisions of this Agreement should, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Agreement, and this Agreement shall be
construed as if such invalid, illegal or unenforceable provision had never been contained herein. Upon such determination that any provision of this Agreement, or the application of any such provision, is invalid, illegal, void or unenforceable, the
Company and the Purchaser shall negotiate in good faith to modify this Agreement so as to effect the original intent of the Company and the Purchaser as closely as possible to the fullest extent permitted by Law in an acceptable manner to the end
that the transactions contemplated hereby and the other Transaction Agreements are fulfilled to the greatest extent possible. 

7.7    Amendment. No provision in this Agreement shall be supplemented, deleted or amended except in
a writing executed by an authorized representative of each of the Purchaser and the Company. Any amendment effected in accordance with this Section 7.7 shall be binding upon each holder of Shares purchased under this Agreement at the time
outstanding, each future holder of all such Shares, and the Company, and any amendment not effected in accordance with this Section 7.7 shall be void and of no effect. 

7.8    Waivers; Delays or Omissions. It is agreed that no delay or omission to exercise any right,
power or remedy accruing to any party, upon any breach, default or noncompliance by another party under this Agreement, shall impair any such right, power or remedy, nor shall it be construed to be a waiver of any such breach, default or
noncompliance, or any acquiescence therein, or of or in any similar breach, default or noncompliance thereafter occurring. It is further agreed that any Consent of any kind or character on any party’s part of any breach, default or
noncompliance under this Agreement or any waiver on such party’s part of any provisions or conditions of the Agreement must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either
under this Agreement, by Law, or otherwise afforded to any party, shall be cumulative and not alternative. Any waiver effected in accordance with this Section 7.8 shall be binding upon each holder of Shares purchased under this Agreement at the time
outstanding, each future holder of all such Shares, and the Company, and any waiver not effected in accordance with this Section 7.8 shall be void and of no effect. 

7.9    Equitable Relief. Each of the Company and the Purchaser hereby acknowledges and agrees that the
failure of the Company to perform its respective agreements and covenants hereunder will cause irreparable injury to the Purchaser, for which damages, even if available, will not be an adequate remedy. Accordingly, the Company hereby agrees that the
Purchaser shall be entitled to the issuance of equitable relief by any court of competent jurisdiction to compel performance of the Company’s obligations. 

7.10    Notices. All notices and other communications under this Agreement must be in writing and are deemed
duly delivered when (a) delivered if delivered personally or by nationally recognized overnight courier service (costs prepaid), (b) sent by facsimile with confirmation of transmission by the transmitting equipment (or, the first Business Day
following such transmission if the date of transmission is not a Business Day) or (c) received or rejected by the addressee, if sent by United States of America certified or registered mail, return receipt requested; in each case to the following
addresses or facsimile numbers and marked to the attention of the individual (by name or title) designated below (or to such other address, facsimile number or individual as a party may designate by notice to the other parties): 

  
 28 

 If to the Company: 

Calithera Biosciences, Inc. 
 343
Oyster Point Blvd., Suite 200 
 South San Francisco, California 94080 

Facsimile:        650-588-5272 

Attention:        Susan M. Molineaux 

 President and Chief Executive Officer 

with a copy (which will not constitute notice) to: 

Cooley LLP 
 3175 Hanover Street

 Palo Alto, CA 94304-1130 

Facsimile: 650-849-7400 

Attention: John T. McKenna 

      Seth J. Gottlieb 

If to the Purchaser: 
 Incyte
Corporation 
 1801 Augustine Cut-Off 

Wilmington, DE 19803 

Facsimile:        +1 (302) 425-2707 

Attention:         General Counsel 

with a copy (which will not constitute notice) to: 

Morgan, Lewis & Bockius LLP 

502 Carnegie Center 
 Princeton,
NJ 08540 
 United States of America 

Facsimile:    +1 (609) 919-6701 

Attention:    Randall Sunberg 

 Emilio Ragosa 

7.11    Expenses. Each party shall pay all costs and expenses that it incurs with respect to the
negotiation, execution, delivery and performance of this Agreement. 

  
 29 

 7.12    Attorneys’ Fees. In the event that any Action is
instituted under or in relation to this Agreement, including without limitation to enforce any provision in this Agreement, the prevailing party in such dispute shall be entitled to recover from the losing party all fees, costs and expenses of
enforcing any right of such prevailing party under or with respect to this Agreement, including without limitation, such reasonable fees and expenses of attorneys and accountants, which shall include, without limitation, all fees, costs and expenses
of appeals. 
 7.13    Titles and Subtitles. The titles of the sections and subsections of the Agreement
are for convenience of reference only and are not to be considered in construing this Agreement. 

7.14    Counterparts. This Agreement may be executed in any number of counterparts (including via
facsimile, PDF or other electronic signature), each of which shall be an original, but all of which together shall constitute one instrument. 

7.15    Pronouns. All pronouns contained herein, and any variations thereof, shall be deemed to refer to the
masculine, feminine or neutral, singular or plural, as to the identity of the parties hereto may require. The words “include,” “includes” and “including” will be deemed to be followed by the phrase “without
limitation”. The meanings given to terms defined herein will be equally applicable to both the singular and plural forms of such terms. All references to “dollars” or “$” will be deemed references to the lawful money of the
United States of America. All exhibits attached hereto and all other attachments hereto are hereby incorporated herein by reference and made a part hereof. 

7.16    Third-Party Beneficiaries. None of the provisions of this Agreement shall be for the benefit of or
enforceable by any Third Party, including any creditor of any party hereto. No Third Party shall obtain any right under any provision of this Agreement or shall by reason of any such provision make any claim in respect of any debt, liability or
obligation (or otherwise) against any party hereto. 
 7.17    No Strict Construction. This Agreement has
been prepared jointly and will not be construed against either party. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto, and no presumption or
burden of proof shall arise favoring or disfavoring any party hereto by virtue of the authorship of any provisions of this Agreement. 

[Signature Page to Follow] 

  
 30 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date set forth in
the first paragraph hereof. 
  

			
	Company:
	
	CALITHERA BIOSCIENCES, INC.
		
	By:	 	 /s/ Susan M. Molineaux

	Name: Susan M. Molineaux
	Title: President and Chief Executive Officer

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date set forth in
the first paragraph hereof. 
  

			
	Purchaser:
	
	INCYTE CORPORATION
		
	By:	 	 /s/ Hervé Hoppenot

	Name: Hervé Hoppenot
	Title: President and Chief Executive Officer

 EXHIBIT A 

JOINT PRESS RELEASE 

			
	

	 	

 Incyte and Calithera Biosciences Announce Global Collaboration 

to Develop and Commercialize CB-1158, a First-in-class, Small 
 Molecule Arginase Inhibitor 

 

	 	•	 	Incyte gains worldwide rights to CB-1158 for hematology and oncology indications 

  

	 	•	 	Calithera to receive a $45 million up-front payment and an $8 million equity investment 

 

	 	•	 	Incyte and Calithera to co-fund global development of CB-1158; Calithera eligible to receive share of profits in the U.S., potential
milestones and royalties on future sales of CB-1158  

  

	 	•	 	Calithera conference call scheduled today at 8:30 a.m. ET, 5:30 a.m. PT 

 WILMINGTON, DE AND SOUTH
SAN FRANCISCO, CA, January 30, 2017 – Incyte Corporation (NASDAQ: INCY) and Calithera Biosciences, Inc. (NASDAQ: CALA) announce today that the companies have entered into a global collaboration and license agreement for
the research, development and commercialization of Calithera’s first-in-class, small molecule arginase inhibitor CB-1158 in
hematology and oncology. CB-1158 is currently being studied in a monotherapy dose escalation trial and additional studies are expected to evaluate CB-1158 in combination
with immuno-oncology agents, including anti-PD-1 therapy. 

“Arginase-expressing tumor-infiltrating myeloid cells have been shown to play an important role in orchestrating the immune suppressive microenvironment
in cancer; but, to date, therapeutic targeting of the arginase enzyme has remained elusive,” said Reid Huber, Ph.D., Incyte’s Chief Scientific Officer. “The addition of this first-in-class, small molecule arginase inhibitor, CB-1158, to our portfolio expands our innovative immuno-oncology pipeline and allows us to continue to advance our
mission of discovering and developing immune-active combination therapies to treat patients with cancer.” 
 “In this strategic partnership with
Incyte, CB-1158 is expected to be evaluated in multiple trials of novel therapeutic combinations, accelerating its development across hematological and oncology indications,” said Susan Molineaux, Ph.D.,
Calithera’s Chief Executive Officer. 

 Terms of the Collaboration  

Under the terms of the collaboration and license agreement, Calithera will receive an up-front payment of
$45 million from Incyte. In addition, Incyte will make an equity investment in Calithera of $8 million through the purchase of shares at a price of $4.65 per share. 

Incyte will receive worldwide rights to develop and commercialize CB-1158 in hematology and oncology and Calithera
will retain certain rights to research, develop and commercialize certain other arginase inhibitors in certain orphan indications. 
 Incyte and Calithera
will jointly conduct and co-fund development of CB-1158, with Incyte leading global development activities. Incyte will fund 70 percent of global development and
Calithera will be responsible for the remaining 30 percent. In the event of regulatory approvals and commercialization of CB-1158, Incyte and Calithera will share in any future U.S. profits and losses
(receiving 60 percent and 40 percent, respectively) and Calithera will be eligible to receive over $430 million in potential development, regulatory and commercialization milestones from Incyte. Per the terms of the agreement,
Calithera will have the right to co-detail CB-1158 in the U.S. and also be eligible to receive from Incyte tiered royalties based on future ex-U.S. sales, with rates ranging from low-to-mid double-digits. 

The agreement also provides that Calithera may choose to opt out of its co-funding obligations. In this scenario,
Calithera would no longer be eligible to receive future U.S. profits and losses but would be eligible to receive up to $750 million in potential development, regulatory and commercialization milestones from Incyte and, if the product is
approved and commercialized, also be eligible to receive reimbursement based on previous development expenditures incurred by Calithera and tiered royalty payments on future global sales of CB-1158, with rates
ranging from low-to-mid double-digits. 
 The transaction is expected to
close in the first quarter of 2017, subject to customary closing conditions. 
 Conference Call and Webcast Information 

Calithera will host a conference call today to discuss this collaboration at 8:30 a.m. ET, 5:30 a.m. PT. Participants may access the call by dialing (855)783-2599 (domestic) or (631)485-4877 (international) and referencing conference ID 58716954. The conference call will also be available by webcast in the Investor
Relations page of Calithera’s website, www.calithera.com. The archived webcast will remain available for replay for 30 days. 
 About
Arginase 
 Arginase is an enzyme produced by immunosuppressive myeloid cells, including myeloid-derived suppressor cells (MDSCs) and neutrophils, which
prevents T-cell and natural killer (NK) cell activation in tumors. Arginase exerts its immunosuppressive effect by depleting the amino acid arginine in the tumor microenvironment which subsequently prevents
activation and proliferation of the immune system’s cytotoxic T-cells and NK-cells. Inhibition 

 
of arginase activity reverses this immunosuppressive block and restores T-cell function. In preclinical models, arginase inhibition has been shown to
enhance anti-tumor immunity and inhibit tumor growth. 
 About Incyte 

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary
therapeutics. For additional information on Incyte, please visit the Company’s website at www.incyte.com. 
 Follow @Incyte on Twitter at
https://twitter.com/Incyte. 
 About Calithera Biosciences 

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor
metabolism and tumor immunology targets for the treatment of cancer. Calithera’s lead product candidate, CB-839, is a potent, selective, reversible and orally bioavailable inhibitor of glutaminase. CB-839 takes advantage of the pronounced dependency many cancers have on the nutrient glutamine for growth and survival. It is currently being evaluated in Phase 1/2 clinical trials in combination with standard of
care agents. CB-1158 is a first-in-class immuno-oncology metabolic checkpoint inhibitor targeting arginase, a critical
immunosuppressive enzyme responsible for T-cell suppression by myeloid-derived suppressor cells. Arginase depletes arginine, a nutrient that is critical for the activation, growth and survival of the
body’s cancer-fighting immune cells, known as cytotoxic T-cells. CB-1158 is currently in a Phase I clinical trial. Calithera is headquartered in South San
Francisco, California. For more information about Calithera, please visit www.calithera.com. 
 Forward-Looking Statements 

Except for the historical information set forth herein, the matters set forth in this press release contain predictions, estimates and other forward-looking
statements, including without limitation statements regarding: whether CB-1158 will successfully advance through clinical studies or will ever be approved for use in humans anywhere or will be commercialized
anywhere successfully or at all; whether CB-1158 will be effective in the treatment of cancer; and whether and when any of the milestone payments or royalties under this collaboration will ever be paid by
Incyte. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: obtaining approval for this planned collaboration;
research and development efforts related to the collaboration programs; the possibility that results of clinical trials may be unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; other market or
economic factors; unanticipated delays; each company’s ability to compete against parties with greater financial or other resources; greater than expected expenses; and such other risks detailed from time to time in each company’s reports
filed with the Securities and Exchange Commission, including the Form 10-Q for the quarter ended September 30, 2016 filed by each company. Each party disclaims any intent or obligation to update these
forward-looking statements. 

 # # # 

Contacts: 
 Incyte Media 

Catalina Loveman 
 +1 302 498 6171 

cloveman@incyte.com 
 Incyte Investors 

Michael Booth, DPhil 
 +1 302 498 5914 

mbooth@incyte.com 
 Calithera 

Jennifer McNealey 
 +1 650-870-1071 
 ir@Calithera.comExhibit

Exhibit 10.1

2017 Management Cash Incentive Plan

 2017 Management Cash Incentive Plan (MIP)
_______________________________________________________________________

Introduction and Objectives

Northfield Bancorp, Inc.’s (A Delaware Corporation) “Northfield” 2017 Management Cash Incentive Plan (the “MIP” or the “Plan”) is designed to motivate, recognize, and reward designated management team members, within appropriate risk management objectives, for their collective contributions to Northfield Bancorp, Inc. and its subsidiaries (the “Company” or the “Bank”).  The Plan focuses on measures that are critical to the Company’s longer-term growth and profitability.  The MIP serves as a critical component of a competitive total compensation package that enables the Company to attract and retain talent needed to drive the Company’s future success.  This MIP is governed by all terms and conditions of the Northfield Management Cash Incentive Plan approved by the Company’s stockholders on May 28, 2014 (the “Governing Plan”), which shall be the prevailing document if the terms and conditions detailed below are unclear or in contradiction to such plan.

Objectives of the plan include:

		
	•
	Align management compensation with Company performance.

		
	•
	Provide clear focus on key strategic business objectives.

		
	•
	Position the Company’s total cash compensation to be competitive with market. 

		
	•
	Enable the Company to attract and retain the talent needed to drive success.

		
	•
	Motivate and reward management for achieving/exceeding performance goals.

		
	•
	Encourage teamwork across the Company’s operating groups.

		
	•
	Balance performance goals and incentives with appropriate risk management objectives.

Eligibility/Participation

		
	•
	Eligibility will be limited to key members of management and key employees.  Participants will be nominated by management and approved by the Compensation Committee.  Unless specifically approved by the Compensation Committee, the Offices of the Chief Risk Officer and Chief Audit Officer are not eligible to participate in the Corporate performance incentive awards.  Incentive awards will be based on individual goals for these employees with goals and final incentive awards to be approved by the Board Committees that the individual reports to.

		
	•
	New employees must be hired by July 1 to participate in that year’s incentive.  Incentive awards for employees hired between January 1 and July 1 will be pro-rated based on the employee’s date of hire (i.e., base salary actually earned in the year).  Participants must maintain a satisfactory level of performance to be eligible for an incentive award.

		
	•
	Participants must be an active employee as of the award payout date to receive an award, unless they are out on disability, in which case they will receive a pro-rata award. 

Performance Period
The performance period and plan operate on a calendar year basis (January 1, 2017– December 31, 2017). 

Performance Gate/Trigger
In order for the incentive plan to activate, Northfield must achieve at least 80% of budgeted net income.  If the Company does not achieve this level of performance, the MIP will not fund awards (corporate or individual) for participants that year.  The Committee, and the respective Board Committees as it relates to the Offices of the Chief Risk Officer and Chief Audit Officer, will retain discretion, at all times, to recommend individual discretionary bonuses.

Incentive Award Opportunity
Each participant will have a target cash incentive opportunity that is expressed as a percentage of base salary.  Cash incentive awards are based, in part, on the Company’s philosophy to target total cash compensation at approximately the 50th percentile of market for executive management, with individual adjustments made for each participant’s specific experience, responsibilities and performance.  The 2017 incentive cash targets consider market practice and the Company’s current base salary levels.  For 2017, participants, as detailed by title below, will have an opportunity to earn a target award as a percentage of base salary for meeting defined goals.  The Actual payouts can range from 0% (for not meeting any performance goals) to up to 150% of target for exceeding all performance goals.

Achieving performance goals will generally result in a full target award.  Actual payouts will vary above and below the target incentive to reflect actual performance relative to the goals and weights.  The Compensation Committee retains the discretion to determine awards relative to goals and may consider other factors in making the award (e.g. extraordinary events).

The total incentive opportunity and range is summarized below.  These are subject to change based on market practice, internal Company practices, and compensation philosophy.

	
					
	 
	Annual Incentive as a % of Base Salary
(in future years these targets may change and be different by tier)

	Positions
	Below Threshold
	Threshold Performance
	Target Performance
	Stretch
Performance

	CEO
	0%
	20%
	40%
	60%

	Pres./COO
	0%
	20%
	40%
	60%

	EVP
	0%
	15%
	30%
	45%

	SVP
	0%
	12.5%-15%
	25-30%
	37.5%-45%

Incentive Plan Measures

For 2017, the Compensation Committee will determine the Corporate performance goal(s) in conformity with the Governing Plan.  A significant portion of all participants’ incentive will be based on our overall corporate performance.  This approach supports our desire to foster a collaborative team-oriented culture among our senior leadership team.  The Compensation Committee, at its sole discretion, may determine to exclude from actual 2017 performance results, items that are considered non-recurring in nature, and not suitable for consideration in measuring financial performance.  In addition to corporate performance, individual/division performance goals will also be considered.  By considering multiple performance goals and perspectives, our plan supports our goal to provide a balanced and reasonable approach to risk management.

Below is a summary of the weighting of awards based on Corporate and Individual/Division Goals:    

	
			
	Role
	Corporate Performance
	Individual/Division Performance

	CEO
	100%
	0%

	Pres./COO
	100%
	0%

	EVP
	80%
	20%

	SVP (Individual percentages to be determined by the CEO)
	0% - 100%
	0% - 100%

Goal Setting

The Corporate Performance goal(s) will be recommended by the Compensation Committee as part of the Board’s annual business planning process, and approved by the Board of Directors.  The Compensation Committee will approve the performance range and weights associated with the Corporate Performance goals. 

The Compensation Committee, at its discretion, may define goals that have a defined threshold, target and stretch performance and payout range.  The relationship between performance goals and payout ranges will be determined by the Compensation Committee.  Once threshold performance is achieved, the award will increase incrementally.  Actual payouts between threshold, target, and stretch will be prorated between levels to reward incremental performance

Individual/Division goals will be developed and recommended by management and approved by the Compensation Committee and the respective Board Committees, as it relates to the Offices of the Chief Risk Officer and Chief Audit Officer, at the beginning of the year.  Generally, Individual goals should be limited to no more than three goals that reflect critical financial and strategic goals.  Each individual goal is at a target payout.  However, where possible, individual goals should also define a threshold and stretch level which will correspond to the appropriate payout in the table immediately above.  Such goals will help clarify potential pay-performance relationship.  In recognition that some individual goals may not be quantitative, the Compensation Committee and the respective Board Committees as it relates to the Offices of the Chief Risk Officer and Chief Audit Officer, retains the discretion to determine payouts in a manner that appropriately reflects performance.  However, such discretion does not apply to a payout that is intended to be qualified performance based compensation under Internal Revenue Code Section 162(m).  

Award Payouts and Discretion of the Compensation Committee

Payouts relative to the target will be recommended by management (except for the CEO), approved by the Compensation Committee and the respective Board Committees as it relates to the Offices of the Chief Risk Officer and Chief Audit Officer, and ratified by the Board of Directors.  In the case of the CEO, the payout will be determined by the Compensation Committee and ratified by the Board of Directors.

Payouts will be made in cash within a reasonable time period after the Company’s independent registered public accounting firm has made its final report to the Audit Committee on the Company’s 2017 consolidated financial statements..  Generally, payouts will occur within two and a half months following the close of the fiscal year.  Awards are calculated based on actual performance relative to target.  Payouts will be based on percentage of base salary earnings (actual earnings, including any deferrals) for the year.  This will allow for ease of calculation of incentives to reflect participants who work a partial year or part time hours.

All award payouts under the Plan are subject to the discretion of the Compensation Committee and the respective Board Committees as it relates to the Offices of the Chief Risk Officer and Chief Audit Officer.  In determining an award level (both corporate awards and individual awards) consideration may be given to the overall performance of the Company and each individual’s performance and may include, but are not limited to, consideration of audit and regulatory findings, internal control assessments and the amount and direction of risk being assumed by the Company.    The Compensation Committee may, at its sole discretion, consider the effect of “passed” audit adjustments proposed by the Company’s independent registered public accounting firm in determining the achievement of the Corporate or Individual goals established under the Plan.

PLAN TERMS AND CONDITIONS 

Plan Authorization 
The Plan is authorized by the Board of Directors of the Company and administered by the Compensation Committee. 
Program Changes or Discontinuance
The Company has developed this plan based on current objectives and business conditions.  The Plan was developed based on existing business, market and economic conditions; current services; and staff assignments.  If substantial changes occur that affect these conditions, services, assignments, or forecasts, the Company may add to, amend, modify, or discontinue any of the terms or conditions of the Plan at any time.
Compensation Committee Discretion
The Compensation Committee may, at its sole discretion, waive, change, or amend the Plan as it deems appropriate.
The Committee and the respective Board Committees, as it relates to the Offices of the Chief Risk Officer and Chief Audit Officer may, at its sole discretion increase or decrease an award based upon its consideration of a Plan participant’s performance or achievements. 
Termination of Employment 
If a Plan participant leaves or is terminated by the Company before awards are paid, no incentive award will be paid.  Participants must be an active employee of the Company on the date the incentive is paid to receive an award.  (See exceptions for death, disability, and retirement below.)  
Disability or Death or Retirement
If a participant is disabled by an accident or illness, his/her bonus award for the Plan period will be prorated so that the award is based on the period of active employment only (i.e. the award will be reduced by the period of time of disability).  
In the event of death, the Company will pay to the participant’s estate the pro rata portion of the award that had been earned by the participant as of the date of death.

Employees who retire will be paid a pro-rata award based on the period of active employment only.  Retirement is defined by terms consistent with the Company’s retirement plan.
No award will be earned on a pro-rata basis for disability, death, or retirement if such an event occurs within six months from the beginning of the Plan year.
Payments made in the event of death, disability or retirement will be made at the same time payment is made to active employees under the Plan.
Ethics and Interpretation
If there is any ambiguity as to the meaning of any terms or provisions of this Plan or any questions as to the correct interpretation of any information contained therein, the Company’s interpretation expressed by the Compensation Committee will be final and binding.
The altering, inflating, and/or inappropriate manipulation of performance/financial results or any other infraction of recognized ethical business standards, will subject the employee to disciplinary action up to and including termination of employment.  In addition, any incentive compensation as provided by the Plan to which the employee would otherwise be entitled will be revoked.
Recoupment of Awards

Participants of this Plan agree that the Company has the right to recoup or “clawback” awards paid under this Plan if the Compensation Committee concludes that such awards were based on information that was later found to be materially incorrect, including awards that were determined, in whole or in part, on financial statement information that is subsequently restated. Participants of the Plan agree that such recoupment would be made in accordance with prevailing laws and regulations.  The Company also has the right to revise its clawback requirements, or policies subject to this Plan, if changes in laws and regulations require (or permit) the Company to do so.  

Miscellaneous 
The Plan will not be deemed to give any participant the right to be retained in the employ of the Company nor will the Plan interfere with the right of the Company to discharge any participant at any time.  
The Compensation Committee will determine on at least an annual basis, those employees of Northfield Bancorp, Inc. and its consolidated subsidiaries that will be eligible to participate in the Plan.
In the absence of an authorized, written employment contract, the relationship between employees and the Company is one of at-will employment.  The Plan does not alter the relationship.  The Plan will not supersede any specific employment contract obligations the Company may have with a Plan participant.
This Plan and the transactions and payments hereunder shall, in all respect, be governed by, and construed and enforced in accordance with applicable governmental laws and regulations.

Each provision in this Plan is severable, and if any provision is held to be invalid, illegal, or unenforceable, the validity, legality, and enforceability of the remaining provisions shall not, in any way, be affected or impaired thereby.
* * * * *

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00266-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00266-of-00352.parquet"}]]